CereVasc raises $85M Series C for minimally invasive hydrocephalus treatment
Summary
CereVasc raised $85 million in Series C financing led by Piper Sandler Merchant Banking, with participation from Bain Capital Life Sciences, Johnson & Johnson's corporate venture capital arm, Medtronic, and Perceptive Xontogeny Venture Funds. The company is developing the eShunt system, a minimally invasive endovascular implant designed to treat normal pressure hydrocephalus without invasive brain surgery. Proceeds will fund the ongoing pivotal trial comparing eShunt to traditional ventriculoperitoneal shunts.
Why it matters
CereVasc's eShunt addresses a critical unmet need in hydrocephalus treatment by eliminating the need to drill a hole in the skull, which carries significant complication rates including 25% readmission within 30 days. Strategic investors J&J and Medtronic validate the technology's commercial potential in a market where no device-based alternatives to surgical shunting currently exist.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial